{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:42:54Z","timestamp":1788514974345,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["30\u2010shi\u20102001"],"award-info":[{"award-number":["30\u2010shi\u20102001"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["20A2015"],"award-info":[{"award-number":["20A2015"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["22A2001"],"award-info":[{"award-number":["22A2001"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fontan-associated liver disease (FALD) is a type of progressive liver fibrosis that occurs following Fontan surgery and can be complicated by hepatocellular carcinoma (HCC). Established treatments for FALD are lacking. Therefore, we investigated the efficacy of ursodeoxycholic acid (UDCA) in patients with FALD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-center retrospective study was conducted from 2003 to 2024 and involved 220 patients (103 men, 46.8%) who had been diagnosed with FALD. UDCA was administered to 113 patients presenting with liver or biliary enzyme abnormalities. We evaluated the patients\u2019 liver enzyme levels 3, 6, and 12 months after treatment. HCC developed in 10.5% and the mortality rate was 4.5%. Survival and cumulative incidence of HCC were compared between patients with and without UDCA treatment using Kaplan\u2013Meier curves and propensity-matched analysis (<jats:italic>n<\/jats:italic> = 68 per group).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>UDCA treatment significantly reduced the aspartate aminotransferase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT) levels at 3 months. The mean pretreatment AST\/ALT\/GGT levels were 26\/22\/323 U\/L, respectively, and decreased to 19\/15\/102 U\/L at 3 months, 18\/12\/88 U\/L at 6 months, and 16\/19\/64 U\/L at 12 months. However, the total bilirubin level and platelet count did not show significant differences. The survival rate was higher and the HCC rate was lower in patients with than without UDCA treatment. The 5-year incidence rate of HCC was 5.6% in the UDCA group and 24.2% in the untreated group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>UDCA treatment significantly reduced liver enzyme levels, including GGT, and mitigated the progression of HCC. UDCA may be beneficial for patients with FALD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00535-024-02168-x","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:39:23Z","timestamp":1732685963000},"page":"210-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-4324","authenticated-orcid":false,"given":"Tomomi","family":"Kogiso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Taniai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Inai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2168_CR1","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep.25692","volume":"56","author":"SK Asrani","year":"2012","unstructured":"Asrani SK, Asrani NS, Freese DK, et al. Congenital heart disease and the liver. Hepatology. 2012;56:1160\u20139. https:\/\/doi.org\/10.1002\/hep.25692.","journal-title":"Hepatology"},{"key":"2168_CR2","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/hep.32406","volume":"75","author":"MB Hilscher","year":"2022","unstructured":"Hilscher MB, Wells ML, Venkatesh SK, et al. Fontan-associated liver disease. Hepatology. 2022;75:1300\u201321. https:\/\/doi.org\/10.1002\/hep.32406.","journal-title":"Hepatology"},{"key":"2168_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.healun.2016.07.011","volume":"36","author":"FM Wu","year":"2017","unstructured":"Wu FM, Earing MG, Aboulhosn JA, et al. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients. J Heart Lung Transplant. 2017;36:211\u20139. https:\/\/doi.org\/10.1016\/j.healun.2016.07.011.","journal-title":"J Heart Lung Transplant"},{"key":"2168_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1056\/NEJMc1306854","volume":"369","author":"RW Elder","year":"2013","unstructured":"Elder RW, Parekh S, Book WM. More on hepatocellular carcinoma after the Fontan procedure. N Engl J Med. 2013;369:490. https:\/\/doi.org\/10.1056\/NEJMc1306854.","journal-title":"N Engl J Med"},{"key":"2168_CR5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jhep.2023.07.013","volume":"79","author":"L T\u00e9llez","year":"2023","unstructured":"T\u00e9llez L, Payanc\u00e9 A, Tjwa E, et al. EASL-ERN position paper on liver involvement in patients with Fontan-type circulation. J Hepatol. 2023;79:1270\u2013301. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.013.","journal-title":"J Hepatol"},{"key":"2168_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14040","author":"S Ohfuji","year":"2024","unstructured":"Ohfuji S, Tanaka A, Kogiso T, et al. Epidemiology of Fontan-associated liver disease in Japan: results from a nationwide survey in 2021. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14040.","journal-title":"Hepatol Res"},{"key":"2168_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/818570","volume":"2015","author":"G Koenig","year":"2015","unstructured":"Koenig G, Seneff S. Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers. 2015;2015: 818570. https:\/\/doi.org\/10.1155\/2015\/818570.","journal-title":"Dis Markers"},{"key":"2168_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0004563215597010","volume":"53","author":"S Bulusu","year":"2016","unstructured":"Bulusu S, Sharma M. What does serum \u03b3-glutamyltransferase tell us as a cardiometabolic risk marker? Ann Clin Biochem. 2016;53:312\u201332. https:\/\/doi.org\/10.1177\/0004563215597010.","journal-title":"Ann Clin Biochem"},{"key":"2168_CR9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1007\/s00380-015-0743-4","volume":"31","author":"M Shimizu","year":"2016","unstructured":"Shimizu M, Miyamoto K, Nishihara Y, et al. Risk factors and serological markers of liver cirrhosis after Fontan procedure. Heart Vessels. 2016;31:1514\u201321. https:\/\/doi.org\/10.1007\/s00380-015-0743-4.","journal-title":"Heart Vessels"},{"key":"2168_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14093","author":"T Kogiso","year":"2024","unstructured":"Kogiso T, Ogasawara Y, Taniai M, et al. Importance of gamma-glutamyl transferase elevation in patients with Fontan-associated liver disease. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14093.","journal-title":"Hepatol Res"},{"key":"2168_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1253\/circj.CJ-17-1053","volume":"82","author":"M Kuwabara","year":"2018","unstructured":"Kuwabara M, Niwa K, Toyoda T, et al. Liver cirrhosis and\/or hepatocellular carcinoma occurring late after the fontan procedure - a nationwide survey in Japan. Circ J. 2018;82:1155\u201360. https:\/\/doi.org\/10.1253\/circj.CJ-17-1053.","journal-title":"Circ J"},{"key":"2168_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13500","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Kogiso T, Sugiyama H, et al. Characteristics of hepatocellular carcinoma arising from Fontan-associated liver disease. Hepatol Res. 2020. https:\/\/doi.org\/10.1111\/hepr.13500.","journal-title":"Hepatol Res"},{"key":"2168_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/heartjnl-2022-320940","volume":"109","author":"R Inuzuka","year":"2023","unstructured":"Inuzuka R, Nii M, Inai K, et al. Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation. Heart. 2023;109:276\u201382. https:\/\/doi.org\/10.1136\/heartjnl-2022-320940.","journal-title":"Heart"},{"key":"2168_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270230","volume":"17","author":"T Kogiso","year":"2022","unstructured":"Kogiso T, Sagawa T, Taniai M, et al. Risk factors for Fontan-associated hepatocellular carcinoma. PLoS ONE. 2022;17: e0270230. https:\/\/doi.org\/10.1371\/journal.pone.0270230.","journal-title":"PLoS ONE"},{"key":"2168_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00535-021-01842-8","volume":"57","author":"R Sakamori","year":"2022","unstructured":"Sakamori R, Yamada R, Tahata Y, et al. The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery. J Gastroenterol. 2022;57:111\u20139. https:\/\/doi.org\/10.1007\/s00535-021-01842-8.","journal-title":"J Gastroenterol"},{"key":"2168_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1006\/bbrc.1999.1403","volume":"263","author":"H Mitsuyoshi","year":"1999","unstructured":"Mitsuyoshi H, Nakashima T, Sumida Y, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263:537\u201342. https:\/\/doi.org\/10.1006\/bbrc.1999.1403.","journal-title":"Biochem Biophys Res Commun"},{"key":"2168_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/BF02779195","volume":"25","author":"H Oka","year":"1990","unstructured":"Oka H, Toda G, Ikeda Y, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol Jpn. 1990;25:774\u201380. https:\/\/doi.org\/10.1007\/BF02779195.","journal-title":"Gastroenterol Jpn"},{"key":"2168_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1440-1746.1998.tb00707.x","volume":"13","author":"I Makino","year":"1998","unstructured":"Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol. 1998;13:659\u201364. https:\/\/doi.org\/10.1111\/j.1440-1746.1998.tb00707.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2168_CR19","doi-asserted-by":"publisher","first-page":"21742","DOI":"10.1038\/s41598-020-78840-y","volume":"10","author":"T Kogiso","year":"2020","unstructured":"Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep. 2020;10:21742. https:\/\/doi.org\/10.1038\/s41598-020-78840-y.","journal-title":"Sci Rep"},{"key":"2168_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/01.sla.0000254368.65878.da","volume":"245","author":"M Minagawa","year":"2007","unstructured":"Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC\/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909\u201322. https:\/\/doi.org\/10.1097\/01.sla.0000254368.65878.da.","journal-title":"Ann Surg"},{"key":"2168_CR21","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.crad.2022.10.012","volume":"78","author":"Y Shiina","year":"2023","unstructured":"Shiina Y, Inai K, Sakai R, et al. Hepatocellular carcinoma and focal nodular hyperplasia in patients with Fontan-associated liver disease: characterisation using dynamic gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI. Clin Radiol. 2023;78:e197\u2013203. https:\/\/doi.org\/10.1016\/j.crad.2022.10.012.","journal-title":"Clin Radiol"},{"key":"2168_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","volume":"472","author":"L Bertero","year":"2018","unstructured":"Bertero L, Massa F, Metovic J, et al. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? Virchows Arch. 2018;472:519\u201331. https:\/\/doi.org\/10.1007\/s00428-017-2276-y.","journal-title":"Virchows Arch"},{"key":"2168_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10715760410001694026","volume":"38","author":"DH Lee","year":"2004","unstructured":"Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535\u20139. https:\/\/doi.org\/10.1080\/10715760410001694026.","journal-title":"Free Radic Res"},{"key":"2168_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/heartjnl-2016-310108","volume":"103","author":"T Alsaied","year":"2017","unstructured":"Alsaied T, Bokma JP, Engel ME, et al. Factors associated with long-term mortality after Fontan procedures: a systematic review. Heart. 2017;103:104\u201310. https:\/\/doi.org\/10.1136\/heartjnl-2016-310108.","journal-title":"Heart"},{"key":"2168_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3892\/or.2011.1239","volume":"25","author":"GE Chung","year":"2011","unstructured":"Chung GE, Yoon JH, Lee JH, et al. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth. Oncol Rep. 2011;25:1739\u201346. https:\/\/doi.org\/10.3892\/or.2011.1239.","journal-title":"Oncol Rep"},{"key":"2168_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113479","volume":"9","author":"Y Xu","year":"2014","unstructured":"Xu Y, Luo Q, Lin T, et al. U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR\/S6K1 and cyclin\/CDK complex pathways. PLoS ONE. 2014;9: e113479. https:\/\/doi.org\/10.1371\/journal.pone.0113479.","journal-title":"PLoS ONE"},{"key":"2168_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.755394","volume":"12","author":"W Lin","year":"2021","unstructured":"Lin W, Li S, Meng Y, et al. UDCA Inhibits hypoxic hepatocellular carcinoma cell-induced angiogenesis through suppressing HIF-1\u03b1\/VEGF\/IL-8 intercellular signaling. Front Pharmacol. 2021;12: 755394. https:\/\/doi.org\/10.3389\/fphar.2021.755394.","journal-title":"Front Pharmacol"},{"key":"2168_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","volume":"79","author":"T Re\u017een","year":"2022","unstructured":"Re\u017een T, Rozman D, Kov\u00e1cs T, et al. The role of bile acids in carcinogenesis. Cell Mol Life Sci. 2022;79:243. https:\/\/doi.org\/10.1007\/s00018-022-04278-2.","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02168-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02168-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:14:34Z","timestamp":1738660474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02168-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2168"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02168-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}